Literature DB >> 14671173

Occult Cushing's syndrome in type-2 diabetes.

Bogdan Catargi1, Vincent Rigalleau, Agathe Poussin, Nathalie Ronci-Chaix, Veronique Bex, Vincent Vergnot, Henri Gin, Patrick Roger, Antoine Tabarin.   

Abstract

Subclinical Cushing's syndrome (SCS) caused by adrenal incidentalomas is frequently associated with overweight and insulin resistance. Metabolic syndrome X may therefore be a clue to the presence of CS. However, the incidence of CS in this situation remains unknown. We have conducted a prospective study to evaluate the prevalence of occult CS in overweight, type-2 diabetic patients devoided of specific clinical symptoms of CS. Two hundred overweight, type-2 diabetic patients, consecutively referred for poor metabolic control (HbA(1C) > 8%), were studied as inpatients. A first screening step was performed with the 1-mg overnight dexamethasone suppression test (DST) using a revised criterion for cortisol suppression (60 nmol/liter) to maximize the sensitivity of the procedure. A second confirmatory step of biochemical investigations (midnight plasma cortisol concentration, plasma cortisol circadian rhythm, morning plasma ACTH concentration, 24-h urinary free cortisol, and 4-mg i.v. DST) was performed in patients with impaired 1-mg DST. A third step of imaging studies was performed according to the results of second-step investigations. Fifty-two patients had impaired 1-mg DST. Among these, 47 were further evaluated. Thirty were considered as false positives of the 1-mg DST, whereas 17 displayed at least one additional biological abnormality of the hypothalamic-pituitary-adrenal axis. Definitive occult CS was identified in four patients (2% of the whole series) with Cushing's disease (n = 3) and surgically proven adrenal adenoma (n = 1). Definitive diagnosis remains to be established in seven additional patients (3.5%) with mild occult CS associated with unsuppressed plasma ACTH concentrations and a unilateral adrenal tumor of 10-29 mm in size showing prevalent uptake at radiocholesterol scintigraphy. In conclusion, a relatively high prevalence of occult CS was found in our study. Further studies are needed to evaluate the impact of the cure of occult CS on obesity and diabetes mellitus in these patients. Such studies might provide a rationale for systematic screening of occult CS in this population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671173     DOI: 10.1210/jc.2003-030254

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  46 in total

1.  Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing's syndrome.

Authors:  Zhanna E Belaya; Alexander V Iljin; Galina A Melnichenko; Liudmila Y Rozhinskaya; Natalia V Dragunova; Larisa K Dzeranova; Svetlana A Butrova; Ekaterina A Troshina; Ivan I Dedov
Journal:  Endocrine       Date:  2012-03-25       Impact factor: 3.633

2.  Effect of treadmill exercise on blood glucose, serum corticosterone levels and glucocorticoid receptor immunoreactivity in the hippocampus in chronic diabetic rats.

Authors:  In Koo Hwang; Sun Shin Yi; Ki-Yeon Yoo; Ok Kyu Park; Bingchun Yan; Wook Song; Moo-Ho Won; Yeo Sung Yoon; Je Kyung Seong
Journal:  Neurochem Res       Date:  2010-11-13       Impact factor: 3.996

Review 3.  Pros and cons of screening for occult Cushing syndrome.

Authors:  Antoine Tabarin; Paul Perez
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 4.  Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications.

Authors:  S Tsagarakis; D Vassiliadi; N Thalassinos
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

5.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 6.  Harmful effects of functional hypercortisolism: a working hypothesis.

Authors:  Giacomo Tirabassi; Marco Boscaro; Giorgio Arnaldi
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

7.  Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States.

Authors:  Michael S Broder; Maureen P Neary; Eunice Chang; Dasha Cherepanov; William H Ludlam
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

8.  Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients.

Authors:  Bradley R Javorsky; Ty B Carroll; Nicholas A Tritos; Roberto Salvatori; Anthony P Heaney; Maria Fleseriu; Beverly M K Biller; James W Findling
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

9.  Midnight salivary cortisol for the diagnosis of Cushing's syndrome in a Chinese population.

Authors:  Dao-Chen Lin; Pei-Shan Tsai; Yi-Chun Lin
Journal:  Singapore Med J       Date:  2018-11-29       Impact factor: 1.858

10.  Specificity of screening tests for Cushing's syndrome in an overweight and obese population.

Authors:  Smita K Baid; Domenica Rubino; Ninet Sinaii; Sheila Ramsey; Arthur Frank; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2009-07-14       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.